Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Rating of "Buy" by Analysts

Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) has been given an average rating of "Buy" by the eleven research firms that are covering the stock, MarketBeat.com reports. Nine investment analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $15.22.

SLDB has been the topic of a number of recent analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and set a $16.00 price target on shares of Solid Biosciences in a research note on Thursday, May 22nd. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of Solid Biosciences in a research note on Tuesday, June 17th. Wedbush cut their price objective on Solid Biosciences from $18.00 to $17.00 and set an "outperform" rating for the company in a research report on Friday, May 16th. Barclays reduced their target price on shares of Solid Biosciences from $15.00 to $10.00 and set an "overweight" rating on the stock in a report on Friday, May 16th. Finally, Piper Sandler decreased their price objective on Solid Biosciences from $20.00 to $17.00 and set an "overweight" rating on the stock in a report on Friday, May 16th.

Solid Biosciences Trading Up 7.8%

SLDB stock traded up $0.35 on Friday, hitting $4.86. The company's stock had a trading volume of 996,191 shares, compared to its average volume of 1,172,476. Solid Biosciences has a 1 year low of $2.41 and a 1 year high of $10.37. The stock has a market cap of $376.70 million, a price-to-earnings ratio of -1.63 and a beta of 2.22. The firm has a 50 day moving average of $3.50 and a two-hundred day moving average of $3.90.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.06). As a group, equities analysts forecast that Solid Biosciences will post -2.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. CWM LLC increased its holdings in Solid Biosciences by 15,188.5% during the 1st quarter. CWM LLC now owns 7,950 shares of the company's stock worth $29,000 after purchasing an additional 7,898 shares during the last quarter. Corton Capital Inc. bought a new stake in shares of Solid Biosciences in the fourth quarter worth $41,000. Ground Swell Capital LLC acquired a new stake in Solid Biosciences in the first quarter valued at $42,000. Invesco Ltd. bought a new position in Solid Biosciences during the 4th quarter valued at $49,000. Finally, Sei Investments Co. acquired a new position in Solid Biosciences during the 4th quarter worth $52,000. Institutional investors and hedge funds own 81.46% of the company's stock.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.